Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 5 results

ea0099ep558 | Endocrine-Related Cancer | ECE2024

99mTechnetium-labeled GRPR antagonist for the imaging of prostate cancer – first clinical images

Bromińska Barbara , A. Nock Berthold , Maina Theodosia , Kaloudi Aikaterini , Kanellopoulos Panagiotis , Janota Barbara , Mikołajczak Renata , Ruchała Marek , Czepczyński Rafał

Introduction: Nuclear medicine procedures offer a possibility of tracing tumor cells based on their physiology. Gastrin-Releasing Peptide receptor (GRPr) is aberrantly expressed in numerous cancers, among them prostate cancer. Demobesin-15 ([99mTc]DB15) is a novel GRPR-antagonist designed for the evaluation of GRPr expression in different tumors. It has been shown to accumulate in animal prostate cancer models. Hereby, we present our experiences with the first in-hu...
0 shares

ea0037gp.28.03 | Endocrine tumours and neoplasia – NETS | ECE2015

Could 99mTc labelled glucagon-like peptide 1 analogue scintigraphy be an answer for patients with persistent hypoglycaemia?

Hubalewska-Dydejczyk Alicja , Sowa-Staszczak Anna , Stefanska Agnieszka , Pach Dorota , Buziak-Bereza Monika , Trofimiuk-Muldner Malgorzata , Gilis-Januszewska Aleksandra , Jabrocka-Hybel Agata , Tomaszuk Monika , Tomaszewska Romana , Malecki Maciej , Bednarczuk Tomasz , Kaminski Grzegorz , Kowalska Aldona , Mikolajczak Renata , Janota Barbara

Surgery is the only effective therapy for insulinoma patients, therefore there is a necessity to develop diagnostic strategies in cases of unknown tumour location, possibly through the use of new biomarkers. 99mTc labelled glucagon-like peptide 1 analogue (99mTc-GLP1) scintigraphy has been developed in our centre as an imaging technique of insulinoma. Labelled GLP1 analogue might also be applied in diagnosis of various forms of nesidioblastosis allowing t...
0 shares

ea0035p583 | Endocrine tumours and neoplasia | ECE2014

99mTc-GLP-1 scintigraphy, an efficient method for the detection of insulinoma: results of 3 years’ experience

Hubalewska-Dydejczyk Alicja , Sowa-Staszczak Anna , Pach Dorota , Tomaszuk Monika , Stefanska Agnieszka , Buziak-Bereza Monika , Jabrocka-Hybel Agata , Gilis-Januszewska Aleksandra , Malecki Maciej , Bednarczuk Tomasz , Kaminski Grzegorz , Kowalska Aldona , Trofimiuk-Muldner Malgorzata , Mikolajczak Renata , Janota Barbara

Introduction: The aim of this study was to assess the diagnostic efficiency of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 scintigraphy in the detection of hardly detectable or not diagnosed by other available method insulinomas.Materials and methods: 37 patients (24 women and 13 men, mean age 46.5±17.8 years, min. 16.0 years, max. 77.0 years) were enrolled in this study. There were 32 patients with clinical and bioch...
0 shares

ea0090p656 | Endocrine-related Cancer | ECE2023

Management of NENs with SSTR2-antagonist: how close are we to a clinical solution? The first results of the TECANT study: Novel 99m-Tc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms – a feasibility study

Hubalewska-Dydejczyk Alicja , Decristoforo Clemens , Kolenc Petra , Mikolajczak Renata , Ležaić Luka , Suden Andrej , Garnuszek Piotr , Simoncic Urban , Virgolini Irene , Trofimiuk-Muldner Malgorzata , Opalinska Marta , Rangger Christine , Glowa Boguslaw , Skorkiewicz Konrad , Fani Melpomeni , Sowa Staszczak Anna , Janota Barbara , Kroselj Marko , Zaletel Katja , Von Guggenberg Elisabeth

Introduction: The management of patients with neuroendocrine neoplasms (NEN) has been revolutionised since the introduction of radiolabelled somatostatin analogues targeting overexpressed somatostatin receptors (SSTR). Accurate assessment of SSTR status of primary focus/metastases is crucial to determine the choice of the treatment method. Recently it has been shown that novel molecular probes, SST2-antagonists, recognize more binding sites in comparison to the wide...
4 shares

ea0099oc7.3 | Oral Communications 7: Endocrine-related Cancer | ECE2024

How close we are to optimise the assessment of SSTR status in NEN with a radiolabelled SSTR antagonist-final results of the TECANT clinical trial: Novel 99mTc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms

Hubalewska-Dydejczyk Alicja , Ležaić Luka , Decristoforo Clemens , Mikolajczak Renata , Virgolini Irene , Kolenc Petra , Suden Andrej , Simoncic Urban , Opalinska Marta , Trofimiuk-Muldner Malgorzata , Garnuszek Piotr , di Santo Gianpaolo , Novak Doroteja , Rangger Christine , Kroselj Marko , Skorkiewicz Konrad , Fani Melpomeni , Janota Barbara , Glowa Boguslaw , Sawicka Agnieszka

Introduction/Aim: Within the past two decades, the imaging and treatment of patients with neuroendocrine neoplasms (NEN) has been redefined by the successful introduction of radiolabelled somatostatin receptor (SSTR)-agonists targeting SSTR-subtype2 (SSTR2) overexpressed in NEN cells. Reliable assessment of the SSTR status of the primary focus/metastasis in different NEN locations is a cornerstone of NEN management and enables a personalised/precise therapeutic appr...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more